Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $11.2 million.

  • Viridian Therapeutics, Inc.\DE's Share-based Compensation rose 2901.38% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.3 million, marking a year-over-year decrease of 3028.22%. This contributed to the annual value of $42.2 million for FY2024, which is 3725.06% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Share-based Compensation stood at $11.2 million, which was up 2901.38% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Share-based Compensation registered a high of $26.0 million during Q4 2023, and its lowest value of $3.2 million during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $9.0 million (2024), whereas its average is $9.3 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Share-based Compensation soared by 54747.97% in 2021, and later tumbled by 6554.44% in 2024.
  • Viridian Therapeutics, Inc.\DE's Share-based Compensation (Quarter) stood at $3.5 million in 2021, then skyrocketed by 51.19% to $5.3 million in 2022, then skyrocketed by 393.52% to $26.0 million in 2023, then crashed by 65.54% to $9.0 million in 2024, then increased by 25.35% to $11.2 million in 2025.
  • Its Share-based Compensation was $11.2 million in Q3 2025, compared to $10.8 million in Q2 2025 and $10.2 million in Q1 2025.